Heron Therapeutics (HRTX) Other Non Operating Income (2014 - 2026)

Heron Therapeutics (HRTX) has 13 years of Other Non Operating Income data on file, last reported at -$3.3 million in Q1 2026.

• Quarterly Other Non Operating Income fell 544.7% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 919.28% YoY) and the FY2025 annual result came in at -$11.3 million, down 2736.98% from the prior year.
• Other Non Operating Income rose to -$3.3 million in Q1 2026, from -$8.0 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.0 million in Q4 2024 to a low of -$8.0 million in Q4 2025.
• A 5-year average of -$1.5 million and a median of -$454500.0 in 2024 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 455.25% — and 2025, when it sank 1310.26%.
• Tracing HRTX's Other Non Operating Income over 5 years: stood at $1.3 million in 2022, then plunged by 105.98% to -$79000.0 in 2023, then surged by 2596.2% to $2.0 million in 2024, then tumbled by 506.34% to -$8.0 million in 2025, then soared by 58.24% to -$3.3 million in 2026.
• The last three Other Non Operating Income figures came in at -$3.3 million (Q1 2026), -$8.0 million (Q4 2025), and -$5.5 million (Q3 2025), per Business Quant data.